相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma
Mohamad Krayem et al.
CANCERS (2020)
Robust gene expression programs underlie recurrent cell states and phenotype switching in melanoma
Jasper Wouters et al.
NATURE CELL BIOLOGY (2020)
MITF and UV responses in skin: From pigmentation to addiction
Nhu T. Nguyen et al.
PIGMENT CELL & MELANOMA RESEARCH (2019)
SIRT2 Contributes to the Resistance of Melanoma Cells to the Multikinase Inhibitor Dasatinib
Iwona Karwaciak et al.
CANCERS (2019)
14-3-3 proteins mediate inhibitory effects of cAMP on salt-inducible kinases (SIKs)
Tim Sonntag et al.
FEBS JOURNAL (2018)
STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network
Julie Delyon et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
Salt-Inducible Kinases: Physiology, Regulation by cAMP, and Therapeutic Potential
Marc N. Wein et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2018)
Dasatinib: A Review in Chronic Myeloid Leukaemia and Ph plus Acute Lymphoblastic Leukaemia
Gillian M. Keating
DRUGS (2017)
P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition
Ahmad Najem et al.
EUROPEAN JOURNAL OF CANCER (2017)
The master role of microphthalmia-associated transcription factor in melanocyte and melanoma biology
Akinori Kawakami et al.
LABORATORY INVESTIGATION (2017)
A UV-Independent Topical Small-Molecule Approach for Melanin Production in Human Skin
Nisma Mujahid et al.
CELL REPORTS (2017)
A Phase 2 Trial of Dasatinib in Patients With Locally Advanced or Stage IV Mucosal, Acral, or Vulvovaginal Melanoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2607)
Kevin Kalinsky et al.
CANCER (2017)
Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial
J. Guo et al.
ANNALS OF ONCOLOGY (2017)
Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy
Michael P. Smith et al.
CANCER CELL (2016)
The activation of melanogenesis by p-CREB and MITF signaling with extremely low-frequency electromagnetic fields on B16F10 melanoma
Yu-Mi Kim et al.
LIFE SCIENCES (2016)
The clinically approved drugs dasatinib and bosutinib induce anti-inflammatory macrophages by inhibiting the salt-inducible kinases
James Ozanne et al.
BIOCHEMICAL JOURNAL (2015)
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition
Richard D. Carvajal et al.
CLINICAL CANCER RESEARCH (2015)
A Closer Look at Evolution: Variants (SNPs) of Genes Involved in Skin Pigmentation, Including EXOC2, TYR, TYRP1, and DCT, Are Associated With 25(OH)D Serum Concentration
Roman Saternus et al.
ENDOCRINOLOGY (2015)
Molecular alterations in signal pathways of melanoma and new personalized treatment strategies: Targeting of Notch
Julija Mozuraitiene et al.
MEDICINA-LITHUANIA (2015)
Molecular alterations in signal pathways of melanoma and new personalized treatment strategies: Targeting of Notch
Julija Mozuraitiene et al.
MEDICINA-LITHUANIA (2015)
MITF in melanoma: mechanisms behind its expression and activity
Mariusz L. Hartman et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2015)
Anti-apoptotic BCL-2 proteins govern cellular outcome following B-RAFV600E inhibition and can be targeted to reduce resistance
M. N. Serasinghe et al.
ONCOGENE (2015)
The roles of microphthalmia-associated transcription factor and pigmentation in melanoma
Jennifer J. Hsiao et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2014)
Transitory dasatinib-resistant states in KITmut t(8;21) acute myeloid leukemia cells correlate with altered KIT expression
Markus D. Hellmann et al.
EXPERIMENTAL HEMATOLOGY (2014)
Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199
S. L. Khaw et al.
LEUKEMIA (2014)
Small-molecule screening identifies inhibition of salt-inducible kinases as a therapeutic strategy to enhance immunoregulatory functions of dendritic cells
Thomas B. Sundberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells
Jason R. Todd et al.
PIGMENT CELL & MELANOMA RESEARCH (2013)
Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells
Y. Cheli et al.
ONCOGENE (2012)
A Phase 2 Trial of Dasatinib in Advanced Melanoma
Harriet M. Kluger et al.
CANCER (2011)
KIT as a Therapeutic Target in Metastatic Melanoma
Richard D. Carvajal et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or Amplification
Jun Guo et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy
J. Rafael Sierra et al.
MOLECULAR CANCER (2010)
The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo
Marie-Pierre Gratacap et al.
BLOOD (2009)
Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors
George D. Demetri et al.
CLINICAL CANCER RESEARCH (2009)
Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates
Scott E. Woodman et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas
I. Satzger et al.
BRITISH JOURNAL OF CANCER (2008)
KIT Gene Mutations and Copy Number in Melanoma Subtypes
Carol Beadling et al.
CLINICAL CANCER RESEARCH (2008)
Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/triple-negative'' breast cancer cell lines growing in vitro
Richard S. Finn et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition
Cristina R. Antonescu et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells
S Nam et al.
CANCER RESEARCH (2005)
Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation
CR Antonescu et al.
CLINICAL CANCER RESEARCH (2005)
cAMP response element binding protein (CREB) activates transcription via two distinct genetic elements of the human glucose-6-phosphatase gene
G Thiel et al.
BMC MOLECULAR BIOLOGY (2005)
Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability
GG McGill et al.
CELL (2002)
Microphthalmia-associated transcription factor (MITF): Multiplicity in structure, function, and regulation
S Shibahara et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS (2001)
分享论文
